Sevikah CHT Tablet 5/20/12.5 mg

Adult dose

This medication should be taken once daily, with or without food, along with water. It is recommended to take it at the same time each day (e.g., in the morning). The dosage may be adjusted as follows, based on blood pressure control: - 5/20/12.5 mg: For patients whose blood pressure is not adequately controlled with the combination therapy of amlodipine/olmesartan medoxomil 5/20 mg. - 5/40/12.5 mg: Amlodipine/olmesartan medoxomil

Child dose

Safety and efficacy in pediatric patients under 18 years of age have not been established, and use is not recommended.

This medication should not be used during the second and third trimesters of pregnancy, as it can cause serious harm to the fetus and newborn. Patients allergic to any of the components in this medication or similar medications, those with severe cardiovascular conditions, or patients with significantly impaired kidney or liver function should not take this drug. Patients with decreased blood volume or electrolyte imbalances may experience hypotension upon initial administration, requiring careful monitoring and observation thereafter. Patients with impaired kidney function, kidney transplant recipients, and patients with renovascular hypertension may experience changes in kidney function when taking this drug, and regular blood tests and monitoring are needed. This medication is not recommended for patients with impaired liver function or those with progressive liver cirrhosis due to the risk of hepatic coma. As this drug lowers blood pressure, it can cause dizziness or drowsiness while driving or operating dangerous machinery, so caution is advised. During treatment, blood electrolyte levels and kidney function should be regularly monitored, and if symptoms of electrolyte imbalance (e.g., muscle cramps, fatigue, anxiety, etc.) occur, medical consultation should be sought immediately. When this drug is taken in conjunction with certain other medications (e.g., lithium, non-steroidal anti-inflammatory drugs), the risk of side effects may increase due to interactions, so it is essential to inform a doctor or pharmacist and be cautious. The use of this drug during breastfeeding is not recommended; if necessary, consideration should be given to stopping breastfeeding or using another treatment option. Its safety and effectiveness have not been established for children under 18 years of age, so it is advisable not to use it in this group. Elderly patients may have decreased kidney and liver function; therefore, treatment should start at a low dose and be administered cautiously. In case of overdose, symptoms such as severe hypotension, palpitations, and electrolyte abnormalities may occur, requiring immediate medical attention.

Serious side effects

Hives, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, pallor, severe rash with fever, blisters, skin peeling, pain in mucous membranes of the mouth/eyes, shortness of breath or difficulty breathing, asthma attacks, cough with fever accompanying respiratory abnormalities, yellowing of the skin or eyes (jaundice), extreme fatigue, sudden and severe headache, thunderclap headache, seizures, confusion, vision disturbances, paralysis, urinary difficulties

Mild side effects

• Peripheral edema
• headache
• dizziness
• upper respiratory tract infection
• nasopharyngitis
• urinary tract infection
• sialadenitis
• leukopenia
• thrombocytopenia
• bone marrow suppression

This medication should be stored in a sealed container to protect it from air and moisture, preferably at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness and prevent degradation.

Appearance

White-orange round film-coated tablets

Package unit

28 tablets (14 tablets/PTP X 2)/carton